BridgeMD
New treatment option for CT Scans
Official title Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations
ClinicalTrials.gov ID: NCT06965790
What this study is testing
What is contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume?
contrast media (Imeron 350, active ingredient Iomeprol) volume according to sex-specific blood volume is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for ct scans.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A large proportion of radiological CT examinations require the intravenous administration of iodine-containing X-ray contrast medium. According to current guidelines, the amount required for CT examinations in the (portal) venous phase is calculated on the basis of body weight (e.g.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Presence of a justifying indication for a CT scan of the thorax and abdomen with application of intravenous contrast medium and a start delay...
- Ability to give informed consent, as well as written and verbal consent to participate in the study available
You likely can't join if
- Cardiorespiratory instability (as assessed by the attending physician)
- Age \<18 years
- Existing or suspected pregnancy
- Known post hepatectomy and/or splenectomy
- Lack of current height (in the same inpatient/outpatient hospital stay) or lack of possibility of height measurement
- Lack of current daily body weight or inability to measure body weight
See the full eligibility criteria
- Presence of a justifying indication for a CT scan of the thorax and abdomen with application of intravenous contrast medium and a start delay corresponding to the portal venous contrast medium phase
- Ability to give informed consent, as well as written and verbal consent to participate in the study available
- Cardiorespiratory instability (as assessed by the attending physician)
- Age \<18 years
- Existing or suspected pregnancy
- Known post hepatectomy and/or splenectomy
- Lack of current height (in the same inpatient/outpatient hospital stay) or lack of possibility of height measurement
- Lack of current daily body weight or inability to measure body weight
- Height under 140 cm or over 220 cm
- Body weight under 50 kg or over 120 kg
- Contraindication to iodine-containing contrast medium (Allergy to contrast media containing iodine, Severe renal insufficiency (eGFR \< 30 ml/min), Hyperthyroidism)
The study team makes the final eligibility decision.
Where it's taking place
- Augsburg, Bavaria, Germany
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Augsburg, Bavaria, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.